ERBB2 and non-small cell lung carcinoma: Yang et al. also demonstrated that HER2 exon 20 YVMA insertion is associated with a higher incidence of lifetime brain metastasis, with estimated 12-month brain metastasis incidence as 40.2% compared with 3.6% in the non-YVMA group in patients with advanced NSCLC and HER2 kinase domain mutations [38].